BACKGROUND: Chemotherapy combinations and addition of cetuximab or bevacizumab to chemotherapy have been shown to improve overall survival of metastatic colorectal cancer (CRC) patients. However, the efficacy of cetuximab when administered after bevacizumab failure is still unknown. METHODS: Fifty-eight consecutive patients diagnosed with advanced colorectal cancer between treated with cetuximab following irinotecan failure were included in our analysis. A multivariate Cox model analysis was performed to estimate the effect of previous bevacizumab regimen on survival. RESULTS: Thirteen (22.4%) were pre-treated with anti-VEGF agents. None of them responded to cetuximab, and this subgroup presented a significantly decreased disease-specific survival as compared to treatment-naïve patients (9.1 months vs. 4.9 months; p=0.026). This difference remained statistically significant in a multivariate Cox model after adjusting for age, sex, performance status (PS), and K-RAS status (RR=2.2; 95% CI: 1.1-4.5, p=0.03). CONCLUSION: These study results suggest that a previous anti-VEGF therapy decrease cetuximab efficiency.
BACKGROUND: Chemotherapy combinations and addition of cetuximab or bevacizumab to chemotherapy have been shown to improve overall survival of metastatic colorectal cancer (CRC) patients. However, the efficacy of cetuximab when administered after bevacizumab failure is still unknown. METHODS: Fifty-eight consecutive patients diagnosed with advanced colorectal cancer between treated with cetuximab following irinotecan failure were included in our analysis. A multivariate Cox model analysis was performed to estimate the effect of previous bevacizumab regimen on survival. RESULTS: Thirteen (22.4%) were pre-treated with anti-VEGF agents. None of them responded to cetuximab, and this subgroup presented a significantly decreased disease-specific survival as compared to treatment-naïve patients (9.1 months vs. 4.9 months; p=0.026). This difference remained statistically significant in a multivariate Cox model after adjusting for age, sex, performance status (PS), and K-RAS status (RR=2.2; 95% CI: 1.1-4.5, p=0.03). CONCLUSION: These study results suggest that a previous anti-VEGF therapy decrease cetuximab efficiency.
Authors: Marc Peeters; Frédéric Forget; Meinolf Karthaus; Manuel Valladares-Ayerbes; Alberto Zaniboni; Gaston Demonty; Xuesong Guan; Fernando Rivera Journal: ESMO Open Date: 2018-02-24
Authors: Richard M Goldberg; Clara Montagut; Zev A Wainberg; Philippe Ronga; François Audhuy; Julien Taieb; Sebastian Stintzing; Salvatore Siena; Daniele Santini Journal: ESMO Open Date: 2018-05-05
Authors: Tomas Buchler; Renata Chloupkova; Alexandr Poprach; Ondrej Fiala; Igor Kiss; Katerina Kopeckova; Ladislav Dusek; Veronika Veskrnova; Lubomir Slavicek; Milan Kohoutek; Jindrich Finek; Marek Svoboda; Lubos Petruzelka; Bohuslav Melichar Journal: Cancer Manag Res Date: 2018-12-28 Impact factor: 3.989